The application of extracorporeal membrane oxygenation in patients with COVID-19: A systematic review and meta-analyses of cohort studies

Q4 Medicine 中国循证医学杂志 Pub Date : 2021-01-01 DOI:10.7507/1672-2531.202101122
S. Yi, M. Mingyuan, G. Qianqian, G. Liheng
{"title":"The application of extracorporeal membrane oxygenation in patients with COVID-19: A systematic review and meta-analyses of cohort studies","authors":"S. Yi, M. Mingyuan, G. Qianqian, G. Liheng","doi":"10.7507/1672-2531.202101122","DOIUrl":null,"url":null,"abstract":"Objective To systematically review the application of extracorporeal membrane oxygenation (ECMO) in patients with coronavirus disease 2019 (COVID-19). Methods PubMed, The Cochrane Library, EMbase, CBM, WanFang Data and CNKI databases were searched for studies on ECMO for COVID-19 from December 1st, 2019 to December 31st, 2020. Two researchers independently screened literature, extracted data, and evaluated the risk of bias of included studies. Meta-analysis was then performed using RevMan 5.3 software. Results A total of 24 studies were included, involving 1 576 acute respiratory distress syndrome (ARDS) patients with COVID-19. The overall mortality of patients was 27.3% (430/1 576). The rate of ECMO treatment was 4.68% (379/1 576), and the survival rate was 69.4% (263/379). The mean duration of mechanical ventilation prior to ECMO treatment for ARDS patients ranged from 2.07±0.40 to 15.89±13.0 days, compared with 1.64±0.78 days and 29.9±3.60 days for ECMO treatment. Of the 11 studies included in the meta-analysis, 84.0% (405/482) patients with ARDS received conventional treatment with COVID-19, and 16.0% (77/482) received ECMO treatment on the basis of conventional treatment with ARDS. Results of meta-analysis showed that there was statistically significant difference in the survival rate of ARDS patients with COVID-19 treated with conventional therapy combined with ECMO or with conventional therapy alone (RR=1.27, 95%CI 1.00 to 1.62, P=0.05). Conclusions This study suggests that the survival rate of COVID-19 patients after ECMO treatment has a tendency to improve. Due to the limitation of quantity and quality of included studies, the above conclusions are needed to be verified by more high-quality studies. © 2021 West China University of Medical Science. All rights reserved.","PeriodicalId":39892,"journal":{"name":"中国循证医学杂志","volume":"21 1","pages":"803-809"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国循证医学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7507/1672-2531.202101122","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To systematically review the application of extracorporeal membrane oxygenation (ECMO) in patients with coronavirus disease 2019 (COVID-19). Methods PubMed, The Cochrane Library, EMbase, CBM, WanFang Data and CNKI databases were searched for studies on ECMO for COVID-19 from December 1st, 2019 to December 31st, 2020. Two researchers independently screened literature, extracted data, and evaluated the risk of bias of included studies. Meta-analysis was then performed using RevMan 5.3 software. Results A total of 24 studies were included, involving 1 576 acute respiratory distress syndrome (ARDS) patients with COVID-19. The overall mortality of patients was 27.3% (430/1 576). The rate of ECMO treatment was 4.68% (379/1 576), and the survival rate was 69.4% (263/379). The mean duration of mechanical ventilation prior to ECMO treatment for ARDS patients ranged from 2.07±0.40 to 15.89±13.0 days, compared with 1.64±0.78 days and 29.9±3.60 days for ECMO treatment. Of the 11 studies included in the meta-analysis, 84.0% (405/482) patients with ARDS received conventional treatment with COVID-19, and 16.0% (77/482) received ECMO treatment on the basis of conventional treatment with ARDS. Results of meta-analysis showed that there was statistically significant difference in the survival rate of ARDS patients with COVID-19 treated with conventional therapy combined with ECMO or with conventional therapy alone (RR=1.27, 95%CI 1.00 to 1.62, P=0.05). Conclusions This study suggests that the survival rate of COVID-19 patients after ECMO treatment has a tendency to improve. Due to the limitation of quantity and quality of included studies, the above conclusions are needed to be verified by more high-quality studies. © 2021 West China University of Medical Science. All rights reserved.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
体外膜氧合在COVID-19患者中的应用:队列研究的系统回顾和荟萃分析
目的系统回顾体外膜氧合(ECMO)在2019冠状病毒病(COVID-19)患者中的应用。方法检索2019年12月1日至2020年12月31日PubMed、Cochrane Library、EMbase、CBM、万方数据和中国知网数据库中关于COVID-19 ECMO的相关研究。两位研究者独立筛选文献,提取数据,并评估纳入研究的偏倚风险。采用RevMan 5.3软件进行meta分析。结果共纳入24项研究,纳入1 576例新冠肺炎急性呼吸窘迫综合征(ARDS)患者。总死亡率为27.3%(430/1 576)。ECMO治愈率为4.68%(379/1 576),生存率为69.4%(263/379)。ECMO治疗前机械通气的平均持续时间为2.07±0.40 ~ 15.89±13.0天,而ECMO治疗前机械通气的平均持续时间为1.64±0.78天和29.9±3.60天。meta分析纳入的11项研究中,84.0%(405/482)的ARDS患者接受了COVID-19的常规治疗,16.0%(77/482)的ARDS患者在常规治疗的基础上接受了ECMO治疗。meta分析结果显示,常规治疗联合ECMO与单独常规治疗合并COVID-19的ARDS患者生存率差异有统计学意义(RR=1.27, 95%CI 1.00 ~ 1.62, P=0.05)。结论新冠肺炎患者经ECMO治疗后生存率有提高的趋势。由于纳入研究数量和质量的限制,上述结论需要更多高质量的研究来验证。©2021华西医科大学。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
中国循证医学杂志
中国循证医学杂志 Medicine-Medicine (all)
CiteScore
0.50
自引率
0.00%
发文量
4677
期刊介绍: The Chinese Journal of Evidence-Based Medicine is the official Chinese language journal of the Cochrane China. The journal aims to present the newest research results and promote the international understanding and development of evidence-based medicine, including decision-making, research, practice, and education. Papers in any of the following fields will be considered: editorial, commentary, systematic review, clinical trial and register, methodology, policy-making and management, drug safety, education, patient safety, and knowledge translation. The journal encourages submissions from interdisciplinary studies and all manuscripts are blind peer reviewed.
期刊最新文献
Public anticipation of clinician graduates in the new era of healthy China: A questionnaire-based cross-sectional study The application of extracorporeal membrane oxygenation in patients with COVID-19: A systematic review and meta-analyses of cohort studies The application and promotion of electronic informed consent Safety of COVID-19 vaccine: A meta-analysis Design of the master protocol platform trial and its application in related fields
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1